Longevity & AgingArtículo de investigaciónAcceso abierto

Cancer Cells Missing MTAP Become Vulnerable to a New Class of PRMT5 and MAT2A Drugs

A review of MTAP-deleted cancers shows MTA-cooperative PRMT5 inhibitors produce ~21% response rates in early trials with less blood toxicity than earlier drugs.

jueves, 19 de noviembre de 2026 1 visualización
Publicado en Cancer Res
Molecular view of a PRMT5 enzyme bound to an MTA molecule and a glowing inhibitor inside a cancer cell nucleus

Resumen

About 10% of cancers lose the MTAP gene, which causes methylthioadenosine (MTA) to build up and partially block the enzyme PRMT5. That leaves these tumor cells dependent on what PRMT5 activity remains. Drugs that lock onto the PRMT5–MTA complex, or that cut off its methyl donor SAM by inhibiting MAT2A, can push PRMT5 activity low enough to kill tumor cells while sparing normal ones. This review covers the preclinical work (cell lines, mouse xenografts) and early phase I human data. Responses were seen in about 21% of evaluable patients on the best-studied agents, with fewer hematologic toxicities than earlier PRMT5 inhibitors. All human data are early, uncontrolled and preliminary, with no survival benefit shown yet. This is an oncology review, not a study of aging itself.

Resumen detallado

Why it matters: Homozygous deletion of MTAP, a gene next to the tumor suppressor CDKN2A, occurs in roughly 10% of cancers and in up to 45% of glioblastomas. It is also common in mesothelioma, urothelial, pancreatic and lung cancers. These tumors are often hard to treat. The deletion creates a specific weakness that normal cells lack. Cancer is a major age-related disease, so precision approaches that spare healthy tissue matter for older adults, although this paper does not address aging biology directly.

The mechanism: MTAP normally breaks down MTA. Without it, MTA accumulates (about 15-fold in cell lines) and competes with SAM for binding to PRMT5, an enzyme that adds symmetric dimethylarginine marks to histones and splicing proteins. PRMT5 ends up partially inhibited (an estimated 26% in one cell line). A second hit, from either an MTA-cooperative PRMT5 inhibitor or a MAT2A inhibitor that depletes SAM, can then push activity close to zero. Earlier PRMT5 inhibitors that did not discriminate between tumor and normal cells caused grade 3 or higher adverse events in 23–51% of patients (mainly anemia and thrombocytopenia) and had objective response rates of 0–7%.

Results: In preclinical work (cell lines and mouse xenografts), MTA-cooperative inhibitors such as BMS-986504/MRTX1719 and AMG 193 selectively suppressed MTAP-deleted cells, inhibited tumor growth and caused little hematologic toxicity. Maximal tumor inhibition tracked with at least 95% SDMA reduction, and the drugs induced intron retention and splicing changes. In phase I trials, BMS-986504 (n=124 evaluable) had a 21% response rate (all partial) and a 70% disease control rate, with a median response duration of 6.9 months. AMG 193 showed a 21.4% response rate at active doses (n=42). Grade 3 or higher adverse events were 12–14%, and anemia was 10% or less. The MAT2A inhibitor IDE397 had a 33% response rate (n=27) but a small sample. AG-270 had a 5% response rate and its trial was terminated. TNG908 produced no responses in 23 glioblastoma patients.

Caveats: The data come from early, mostly single-arm trials, with no randomized comparisons, no overall or progression-free survival benefit demonstrated, and short follow-up (median 7.6 months for BMS-986504). Some conference-based data are preliminary. Dose-limiting toxicities included seizure, encephalopathy and gastrointestinal effects. Mechanism and tumor response were shown, but survival has not been.

Hallazgos clave

  • MTAP loss raises MTA about 15-fold, partially inhibiting PRMT5 and creating a tumor-specific synthetic lethal vulnerability (cell-line mechanism data).
  • Earlier non-selective PRMT5 inhibitors had 23–51% grade ≥3 adverse events and 0–7% response rates in human trials.
  • BMS-986504 phase I: 21% response and 70% disease control in 124 evaluable patients; grade ≥3 adverse events 12%, anemia ≤10%.
  • AMG 193 reached a 21.4% response rate at active doses (n=42); TNG908 had no responses in 23 glioblastoma patients.
  • MAT2A inhibitors had mixed results: IDE397 33% response (n=27), AG-270 5% with trial terminated; no survival benefit shown for any agent.

Metodología

Narrative review of preclinical studies (biochemical assays, RNAi screens, cell lines, mouse xenografts) and early phase I/Ib human trials of PRMT5 and MAT2A inhibitors. Clinical figures come from reported trial summaries, some from presentations and press releases. No systematic search method or pooled analysis is described.

Limitaciones del estudio

Human data are early-phase, single-arm and uncontrolled, with short follow-up and no demonstrated survival benefit. Preclinical xenograft findings may not translate, and some trial data are only preliminary. Cross-trial comparisons are unreliable because patient populations and doses differ.

¿Te ha gustado este resumen?

Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.

Introduce tu correo electrónico para suscribirte: